JP7222347B2 - 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 - Google Patents

可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 Download PDF

Info

Publication number
JP7222347B2
JP7222347B2 JP2019514691A JP2019514691A JP7222347B2 JP 7222347 B2 JP7222347 B2 JP 7222347B2 JP 2019514691 A JP2019514691 A JP 2019514691A JP 2019514691 A JP2019514691 A JP 2019514691A JP 7222347 B2 JP7222347 B2 JP 7222347B2
Authority
JP
Japan
Prior art keywords
residue
amino acid
group
salt
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019514691A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2018199337A1 (ja
Inventor
慧 山田
豊 松田
友博 藤井
奈都紀 敷田
玲子 湯地
和高 新保
祐二 伊東
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7222347(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of JPWO2018199337A1 publication Critical patent/JPWO2018199337A1/ja
Priority to JP2023015725A priority Critical patent/JP7708133B2/ja
Application granted granted Critical
Publication of JP7222347B2 publication Critical patent/JP7222347B2/ja
Priority to JP2025113314A priority patent/JP7754361B2/ja
Priority to JP2025166056A priority patent/JP2025185050A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019514691A 2017-04-28 2018-04-27 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 Active JP7222347B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023015725A JP7708133B2 (ja) 2017-04-28 2023-02-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025113314A JP7754361B2 (ja) 2017-04-28 2025-07-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025166056A JP2025185050A (ja) 2017-04-28 2025-10-02 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017090679 2017-04-28
JP2017090679 2017-04-28
PCT/JP2018/017345 WO2018199337A1 (ja) 2017-04-28 2018-04-27 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023015725A Division JP7708133B2 (ja) 2017-04-28 2023-02-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Publications (2)

Publication Number Publication Date
JPWO2018199337A1 JPWO2018199337A1 (ja) 2020-03-12
JP7222347B2 true JP7222347B2 (ja) 2023-02-15

Family

ID=63918939

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019514691A Active JP7222347B2 (ja) 2017-04-28 2018-04-27 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2023015725A Active JP7708133B2 (ja) 2017-04-28 2023-02-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025113314A Active JP7754361B2 (ja) 2017-04-28 2025-07-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025166056A Pending JP2025185050A (ja) 2017-04-28 2025-10-02 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023015725A Active JP7708133B2 (ja) 2017-04-28 2023-02-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025113314A Active JP7754361B2 (ja) 2017-04-28 2025-07-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025166056A Pending JP2025185050A (ja) 2017-04-28 2025-10-02 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Country Status (8)

Country Link
US (2) US12024549B2 (enExample)
EP (2) EP4603507A3 (enExample)
JP (4) JP7222347B2 (enExample)
KR (3) KR20240046307A (enExample)
CN (1) CN110637036A (enExample)
AU (2) AU2018259856B2 (enExample)
CA (1) CA3061467A1 (enExample)
WO (1) WO2018199337A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291395B2 (ja) * 2017-06-16 2023-06-15 国立大学法人 鹿児島大学 ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
EP3808760A4 (en) * 2018-06-14 2022-10-05 Ajinomoto Co., Inc. COMPOUND WITH AFFINITY FOR ANTIBODY, CLEAVAGE SITE AND REACTIVE GROUP OR SALT THEREOF
JPWO2019240288A1 (ja) * 2018-06-14 2021-07-26 味の素株式会社 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
JPWO2020090979A1 (ja) * 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
CN113631539B (zh) * 2019-01-23 2025-08-15 阿比蒂斯有限公司 用于制备抗体-载荷部分偶联物的化合物及其用途
WO2020184944A1 (ko) * 2019-03-08 2020-09-17 앱티스 주식회사 위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트
CA3155284A1 (en) 2019-10-24 2021-04-29 Yuji Ito Method for producing monovalent ccap product
AU2020388383A1 (en) * 2019-11-18 2022-03-31 Kleo Pharmaceuticals, Inc. Directed conjugation technologies
US20230046947A1 (en) * 2019-12-03 2023-02-16 Debiopharm Research & Manufacturing S.A. Reactive conjugates
WO2022078566A1 (en) * 2020-10-12 2022-04-21 Debiopharm Research & Manufacturing S.A. Reactive conjugates
CA3208290A1 (en) 2021-01-18 2022-07-21 Ajinomoto Co., Inc. Compound or salt thereof, and antibody obtained by using the same
CN116829573A (zh) * 2021-01-18 2023-09-29 味之素株式会社 化合物或其盐、及由它们得到的抗体
WO2022191283A1 (ja) 2021-03-11 2022-09-15 味の素株式会社 化合物またはその塩、およびそれらにより得られる抗体
JPWO2022196675A1 (enExample) 2021-03-16 2022-09-22
CN113292633B (zh) * 2021-05-13 2023-08-29 中国科学技术大学 可见光诱导甘氨酸衍生物的肼化修饰方法
KR20240012380A (ko) * 2021-05-17 2024-01-29 바이오하벤 테라퓨틱스 리미티드 지향 접합 기술용 제제 및 접합 생성물
JP2024521092A (ja) * 2021-05-19 2024-05-28 バイオヘイブン・セラピューティクス・リミテッド 細胞傷害性薬剤を送達するためのｍａｔｅｓ技術を使用する抗体薬物コンジュゲート
EP4349373A1 (en) 2021-06-01 2024-04-10 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound
CA3224147A1 (en) 2021-07-09 2023-01-12 Vijaya Raghavan PATTABIRAMAN Antibody conjugates and manufacture thereof
WO2023281479A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023281483A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified tnf-antibodies and uses thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
JP2024529297A (ja) 2021-07-09 2024-08-06 ブライト ピーク セラピューティクス エージー Ｉｌ－２を有するチェックポイント阻害剤のコンジュゲート及びその使用
CA3231257A1 (en) 2021-09-08 2023-03-16 Yuji Ito Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody
WO2023054714A1 (ja) 2021-09-30 2023-04-06 味の素株式会社 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
KR20240073035A (ko) 2021-09-30 2024-05-24 아지노모토 가부시키가이샤 항체 및 기능성 물질의 컨쥬게이트 또는 그 염, 및 그 제조에 사용되는 항체 유도체 및 화합물 또는 그 염
EP4482531A1 (en) 2022-02-23 2025-01-01 Bright Peak Therapeutics AG Immune antigen specific il-18 immunocytokines and uses thereof
US20250163101A1 (en) 2022-03-04 2025-05-22 AbTis Co., Ltd. Method for increasing production yield of antibody-drug conjugate by using thiol-reactive additive
CN116836235A (zh) * 2022-03-25 2023-10-03 中国科学院上海药物研究所 亲和片段导向的可裂解片段，其设计、合成及在制备定点药物偶联物中的应用
JPWO2023234416A1 (enExample) * 2022-06-02 2023-12-07
KR20240125071A (ko) 2022-11-01 2024-08-19 앱티스 주식회사 Fc 결합성 유닛을 포함하는 화합물 및 이를 이용하여 제조된 컨쥬게이트
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
US20240424127A1 (en) 2023-01-11 2024-12-26 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
EP4682173A1 (en) * 2023-03-15 2026-01-21 Kagoshima University Method for producing radiolabeled antibody, radiolabeled antibody, and radioactive medicine
KR20250172615A (ko) 2023-04-04 2025-12-09 아지노모토 가부시키가이샤 항체 및 기능성 물질의 컨쥬게이트, 항체 유도체 및 화합물, 또는 그것들의 염
JPWO2024210178A1 (enExample) 2023-04-05 2024-10-10
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250144234A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics Inc. RNA for In vivo Transfection with Increased Expression
US20250332281A2 (en) 2023-12-15 2025-10-30 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025181697A1 (en) 2024-02-26 2025-09-04 Biohaven Therapeutics Ltd. Bifunctional degraders of anti-pla2r antibody
WO2025210538A1 (en) 2024-04-02 2025-10-09 Biohaven Therapeutics Ltd. Bifunctional degraders
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191883A1 (en) 2014-06-12 2015-12-17 Dophen Biomedical Homogenous antibody drug conjugates via enzymatic methods
JP2016523900A (ja) 2013-06-24 2016-08-12 ハンファ ケミカル コーポレーションＨａｎｗｈａ Ｃｈｅｍｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 安定性が改善された抗体−薬物結合体およびこれの用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
JP3825502B2 (ja) * 1996-06-11 2006-09-27 日本油脂株式会社 修飾蛋白質の製造法及びコンタクトレンズ用汚れ除去剤
ATE218892T1 (de) * 1997-11-07 2002-06-15 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
EP1757311B1 (en) 1999-12-24 2009-02-11 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
DE60030323T2 (de) 1999-12-24 2007-10-11 Genentech, Inc., South San Francisco Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
DE10162773A1 (de) 2001-12-20 2003-07-10 Knf Flodos Ag Sursee Dosierpumpe
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
NZ550934A (en) 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
JP5167473B2 (ja) 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
US8637656B2 (en) 2005-07-05 2014-01-28 Ribomic Inc. Nucleic acid capable of binding to immunoglobulin G and use thereof
EP1989547A1 (en) 2006-02-28 2008-11-12 Medical Research Council Targeted iron oxide nanoparticles
EP2093287A4 (en) 2006-11-02 2010-04-21 Univ Kagoshima PEPTIDE BINDER IGG
WO2008056346A2 (en) 2006-11-10 2008-05-15 Covx Technologies Ireland Limited Anti-angiogenic compounds
WO2011121560A2 (en) * 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
CN103890174B (zh) 2011-08-24 2015-12-23 大塚化学株式会社 IgG结合性肽及利用其检测和纯化IgG的方法
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
US20160000933A1 (en) * 2014-07-01 2016-01-07 Andrei POLUKHTIN Conjugated biological molecules and their preparation
JP5827769B1 (ja) 2015-03-27 2015-12-02 義徳 川窪 掃除装置
US10227383B2 (en) * 2015-05-20 2019-03-12 Kagoshima University Specific modification of antibody with IgG-binding peptide
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
BR112018012388A2 (pt) 2015-12-18 2018-12-04 Eisai R&D Management Co., Ltd. imunoglobulinas conjugadas de lisina terminal-c
JP7020403B2 (ja) * 2016-05-02 2022-02-16 味の素株式会社 アジド基含有Ｆｃタンパク質
CN109071606A (zh) * 2016-06-13 2018-12-21 国立大学法人鹿儿岛大学 利用IgG结合肽的位点特异性放射性同位素标记抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523900A (ja) 2013-06-24 2016-08-12 ハンファ ケミカル コーポレーションＨａｎｗｈａ Ｃｈｅｍｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 安定性が改善された抗体−薬物結合体およびこれの用途
WO2015191883A1 (en) 2014-06-12 2015-12-17 Dophen Biomedical Homogenous antibody drug conjugates via enzymatic methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry，2017年01月，vol.25, no.2, p.351-361
Int. J. Mol. Sci.，2016年，vol.17, no.2, 194
Protein Cell，2016年10月，vol.9, no.1，p.33-46

Also Published As

Publication number Publication date
EP3617235A4 (en) 2020-12-16
EP3617235A1 (en) 2020-03-04
KR20240046307A (ko) 2024-04-08
AU2018259856A1 (en) 2019-11-14
EP4603507A3 (en) 2025-10-29
CA3061467A1 (en) 2019-10-24
US20240366783A1 (en) 2024-11-07
AU2025206404A1 (en) 2025-08-28
JP7708133B2 (ja) 2025-07-15
US20200190165A1 (en) 2020-06-18
EP4603507A2 (en) 2025-08-20
JPWO2018199337A1 (ja) 2020-03-12
JP2023052910A (ja) 2023-04-12
US12024549B2 (en) 2024-07-02
JP7754361B2 (ja) 2025-10-15
AU2018259856A2 (en) 2019-11-28
AU2018259856B2 (en) 2025-05-01
JP2025133878A (ja) 2025-09-11
JP2025185050A (ja) 2025-12-18
CN110637036A (zh) 2019-12-31
KR20200002858A (ko) 2020-01-08
KR20240111015A (ko) 2024-07-16
WO2018199337A1 (ja) 2018-11-01

Similar Documents

Publication Publication Date Title
JP7754361B2 (ja) 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP7413999B2 (ja) 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
EP3882261A1 (en) Compound comprising substance with affinity for antibody, cleavage site and reactive group, or salt thereof
KR102880460B1 (ko) 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염
JP2025124732A (ja) 化合物またはその塩、およびそれらにより得られる抗体
KR102921757B1 (ko) 항체에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230117

R150 Certificate of patent or registration of utility model

Ref document number: 7222347

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250